Calming a younger patient.

Prophylactic Antiemetic Regimen Effective in Pediatric Hematologic Malignancies

Fosaprepitant as antiemetic prophylaxis during treatment with moderately and highly emetogenic chemotherapy appears to be safe, efficacious, and feasible in pediatric patients with hematologic malignancies who are younger than 12 years, according to results from a retrospective study. Researchers from Germany reported at the 2017 American Society of Hematology Annual Meeting (ASH 2017) that a…

Next post in Leukemia